Abstract Library

#4526 The relationship between adherence to traditional Chinese medicine and disease progression in type 1 gastric neuroendocrine tumours: A case report

Introduction: Type 1 gastric neuroendocrine tumours (g-NETs) have a high recurrence risk after endoscopic resection, underscoring the need for regular endoscopic follow-up. Our research hints that Traditional Chinese Medicine (TCM) could help lower recurrence rates.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Cheng Z, Yu F, Chen R, Chen X,

Keywords: type 1 gastric neuroendocrine tumour, Traditional Chinese Medicine, regular follow-up, case report,

#3988 Management and surveillance for rectal neuroendocrine tumors: A single-centre retrospective analysis and comparison with ENETS guidelines

Introduction: Rectal neuroendocrine tumors (rNETs) are rare but are increasing in incidence. Current management and surveillance recommendations are primarily based on low-grade evidence.

Conference:

Presenting Author:

Authors: Barnard P,

Keywords: rectal neuroendocrine tumor, R1 resection, ENETS guideliens,

#3807 Key device attributes for Somatostatin Receptor Ligand (SRL) therapy in patients with neuroendocrine tumors (NETs)

Introduction: SRL injection effectiveness, safety and adherence are similar for independent vs healthcare setting administration, but patient preferences and satisfaction with devices vary. For other injectable hormones, device ease of use has been associated with more favourable outcomes. Elucidating preferred SRL device features should help HCPs decide which device best fits individual needs.

Conference:

Presenting Author: Martin W

Authors: Martin W, Kolarova T, Marks M, Follin C, de Herder W,

Keywords: NET, neuroendocrine tumor, somatostatin receptor ligands, SRL, device, preference,

#3482 PANDORA-2 protocol - Intervention study to improve quality of life in patients with small (≤2 cm) non-functional pancreatic neuroendocrine tumors

Introduction: Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.

Conference:

Presenting Author: Chen J

Authors: Chen J, Heidsma C, Engelsman A, Nieveen van Dijkum E,

Keywords: neuroendocrine, pancreatic, quality of life, ≤2 cm, non-functional, protocol,

#3276 Increasing compliance of an oral oncolytic through a novel clinical nurse educator model

Introduction: A patient education platform to help navigate medication coordination and symptom management leads to improved adherence and effective patient-HCP communication. Historically, cancer patients have lower rates of oral therapy adherence (~16%) versus patients receiving infusion therapy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Gaytan P, Weinman L, Early J, Ricardi D, Kifle B,

Keywords: adherence, clinical nurse educator, CNE, NSP, nurse support program, oral oncolytic,